All News

Found 100 articles

• Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)

  11/10/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on its lead immunotherapy candidate NL-201, an IL-2 and IL-15 agonist, at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting

• Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update

  11/9/2020

  Ended 3rd quarter with $201.2 million in cash and cash equivalents

• Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo

  11/5/2020

  - I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – - Designed to r esist viral mutational escape b y mimicking the natural target of the s pike protein  -

• Taro Provides Results for September 30, 2020

  10/28/2020

  Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020.

• Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

  10/20/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Holly K. Vance as General Counsel.

• Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development

  10/19/2020

   Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corpo

• Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)

  10/14/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of a preclinical data abstract on its lead therapeutic candidate, NL-201, at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting

• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Maze Therapeutics Expands Experienced Management Team with Appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer

  10/6/2020

  Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s chief medical officer. Dr. Noonberg brings significant industry and clinical experience to Maze as the company works to advance its pipeline. “Sarah is an exceptional leader who has helped guide multiple companies through various sta

• Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors

  9/10/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer of Principia Biopharma, Inc. (NASDAQ: PRNB), to the company’s Board of Directors.

• Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 9:30 a.m. Eastern Time.

• Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update

  8/12/2020

  NL-201 IND submission anticipated during fourth quarter of 2020 Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023 Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein

• Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference

  8/6/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that management will participate in a fireside chat at the virtual Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 8:30 a.m. Eastern Time. A live audio webcast of the session will be available from the investors section of the Neo

• Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020

  8/5/2020

  Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced it will report second quarter 2020 financial results on Wednesday, August 12, 2020 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows

• Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics

  7/20/2020

   Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer. Notch is applying its scalable Engineered Thymic Niche (ETN) te

• Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

  7/2/2020

  Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share. In addition, and in lieu of common stock, Neoleukin is offering to certain investors pre-funded warrants to purchase up to an aggre

• Neoleukin Therapeutics Announces Proposed Public Offering

  7/1/2020

  Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.

• Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

  6/22/2020

  - NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company to host Investor R&D Showcase Tuesday, June 23 at 3:30 p.m. PT / 6:30 p.m. ET - SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical com

• Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics

  6/15/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced it will host a virtual Investor R&D Showcase on Tuesday, June 23, 2020 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time. The event will feature an overview of presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II as w

• Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors

  6/1/2020

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of Directors.